Candel Therapeutics: Strong Buy On Aglatimagene Prostate Cancer BLA Filing In Q4

Summary Candel Therapeutics, Inc. is upgraded from Buy to Strong Buy, driven by phase 3 success in localized prostate cancer. The company's aglatimagene met the primary endpoint in a pivotal trial, reducing disease recurrence risk by 30% and supporting a BLA filing in Q4 2026. Upcoming catalysts include phase 3 biomarker data at ASTRO 2026 and advancing aglatimagene in metastatic NSCLC with the AURORA trial. The company is well-capitalized through Q1 2028, with a $100M milestone payment contingent on U.S. approval and a $10–16B addressable market in prostate cancer. Looking for a portfolio of ideas like this one? Members of Biotech Analysis Central get exclusive access to our subscriber-only portfolios. Learn More » Cholada Hongsaeng/iStock via Getty Images The last time I wrote about Candel Therapeutics, Inc. ( CADL ) it was with a Seeking Alpha article entitled " Candel Therapeutics: CAN-2409 May Go Beyond Scope Of Targeting Pancreatic Cancer ." With This article was written by Terry Chrisomalis 15.17K Followers Follow Terry Chrisomalis is a private investor in the Biotech sector with years of experience utilizing his Applied Science background to generate long term value from Healthcare. He is the author of the investing group Biotech Analysis Central which contains a library of 600+ Biotech investing articles, a model portfolio of 10+ small and mid-cap stocks with deep analysis for each, live chat, and a range of analysis and news reports to help Healthcare investors make informed decisions. Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.